| Literature DB >> 24688376 |
Amber Vyas1, Avinesh Kumar Sonker1, Bina Gidwani1.
Abstract
Approximately 95% of the population suffers at some point in their lifetime from acne vulgaris. Acne is a multifactorial disease of the pilosebaceous unit. This inflammatory skin disorder is most common in adolescents but also affects neonates, prepubescent children, and adults. Topical conventional systems are associated with various side effects. Novel drug delivery systems have been used to reduce the side effect of drugs commonly used in the topical treatment of acne. Topical treatment of acne with active pharmaceutical ingredients (API) makes direct contact with the target site before entering the systemic circulation which reduces the systemic side effect of the parenteral or oral administration of drug. The objective of the present review is to discuss the conventional delivery systems available for acne, their drawbacks, and limitations. The advantages, disadvantages, and outcome of using various carrier-based delivery systems like liposomes, niosomes, solid lipid nanoparticles, and so forth, are explained. This paper emphasizes approaches to overcome the drawbacks and limitations associated with the conventional system and the advances and application that are poised to further enhance the efficacy of topical acne formulations, offering the possibility of simplified dosing regimen that may improve treatment outcomes using novel delivery system.Entities:
Mesh:
Substances:
Year: 2014 PMID: 24688376 PMCID: PMC3934386 DOI: 10.1155/2014/276260
Source DB: PubMed Journal: ScientificWorldJournal ISSN: 1537-744X
Figure 1Difference between normal skin and skin with acne.
Types of acne.
| Sr. no | Type of acne | Features |
|---|---|---|
| 1 | Comedonal (noninflammatory) |
|
|
| ||
| 2 | Papulopustular (inflammatory) |
|
|
| ||
| 3 | Nodular (inflammatory) |
|
Types of acne according to severity.
| Sr. no | Type of acne | Features |
|---|---|---|
| 1 | Mild acne | Fewer than 20 comedones or fewer than 15 inflammatory lesions, or total lesion count fewer than 30 |
|
| ||
| 2 | Moderate acne | 20–100 comedones, or 15–50 inflammatory lesions, or total lesion count 30–125 |
|
| ||
| 3 | Severe acne | More than 5 nodules, or Total inflammatory count greater than 50, or Total lesion count greater than 125 |
Figure 2Future forecast of acne.
Figure 3Treatment strategies used for acne.
Topical conventional delivery system used for acne.
| Conventional delivery system | Drug | Side effects | Reference |
|---|---|---|---|
| Lotion | Benzoyl peroxide | Peeling, itching, redness, dryness, burning, and dermatitis | [ |
| Clindamycin | Peeling, itching, redness, dryness | [ | |
| Tretinoin | Erythema, scaling, burning | [ | |
| Erythromycin | Erythema, scaling, burning | [ | |
| Glycolic acid | Itching, rash, pruritus | [ | |
| Tretinoin | Itching, rash, pruritus | [ | |
|
| |||
| Cream | Adapalene | Erythema, scaling, dryness, burning, stinging, irritation, sunburn | [ |
| Tazarotene | Erythema, scaling, burning | [ | |
| Azelaic acid | Itching, rash, pruritus | [ | |
| Tea oil | Burning, itching, irritation, stinging | [ | |
| Clindamycin | Erythema, desquamation | [ | |
|
| |||
| Gel | Salicylic acid | Erythema, dryness, dermatitis | [ |
| Erythromycin | Dryness, erythema, peeling, dermatitis | [ | |
| Benzoyl peroxide | Dryness, erythema, peeling, dermatitis | [ | |
| Adapalene | Erythema, scaling, dryness, burning, stinging, irritation | [ | |
| Dapsone | Peeling, itching, redness, burning | [ | |
|
| |||
| Emollient | Sodium sulfacetamide-sulfur | Dryness, irritation, redness, scaling, stinging, or burning | [ |
Figure 4Novel carrier-based drug delivery system for treatment of acne.
Novel carrier-based delivery system for acne.
| Drug | Objective | Outcomes | Reference |
|---|---|---|---|
| Liposomal formulation | |||
| Benzoyl peroxide | To improve the antibacterial efficacy of benzoyl peroxide | A significant antibacterial effect in the infundibula against both | [ |
| Clindamycin | To improve the stability and penetrability | Increased stability and intradermal penetrability | [ |
| Salicylic acid | To reduce associated side effects | Liposomal formulation produced fivefold higher deposition of drug in skin than the corresponding plain drug solution and conventional gel and reduced skin irritation was observed. | [ |
| Tretinoin | To improve the stability and the thermodynamic activity | Increased stability and drug retention were achieved. | [ |
| Isotretinoin | To increase skin targeting and skin deposition and reduce skin irritation. | Increase skin targeting, drug deposition and decrease skin irritation were observed. | [ |
| Lauric acid | To evaluate the antimicrobial activity | Lauric acid loaded liposomes release the drug directly into the bacterial membranes, thereby killing the bacteria effectively. | [ |
| Cyproterone acetate | To increase percutaneous absorption | Better penetration was observed | [ |
| Finasteride | To increase skin permeation, deposition, and stability of the drug. | Higher deposition of drug in skin, increased permeation and stability were observed. | [ |
| Tea oil | To increase skin permeability of drug. | Tea oil liposome disrupted the permeability barrier of cell membrane structures and increased the permeability. | [ |
| Methylene blue | To evaluate the efficacy and tolerability of liposomes loaded methylene blue. | Liposomal formulation delivered the methylene blue to sebaceous gland and was effective in treatment of mild-to-moderate acne vulgaris. | [ |
|
| |||
| Niosome formulation | |||
| Benzoyl peroxide | To reduce the associated side effects | Niosomal gel improved the skin retention, therapeutic response and considerably reduced the adverse symptoms. | [ |
| Tretinoin | To improve skin drug retention of drug and increase photostability. | Niosomal formulation improved the cutaneous or transdermal delivery of a lipophilic tretinoin and increased photostability. | [ |
| Erythromycin | To enhance drug retention into skin and improve stability. | Niosomal gel was significantly more stable as compared to plain drug gel and marketed gel and drug retention was increased. | [ |
|
| |||
| Microsponge formulation | |||
| Benzoyl peroxide | To reduce skin irritation. | Controlled release and reduced skin irritation | [ |
| Tretinoin | To reduce cutaneous side effect | Controlled release of tretinoin with reduced cutaneous side effects. | [ |
|
| |||
| Microemulsion formulation | |||
| Tretinoin | To increase skin permeation and skin retention. | Novel microemulsion increases tretinoin penetration through skin and maximum amount of drug retained as compare to plain drug in solution, gel and marketed preparation. | [ |
| Retinoic acid | To increase lipophilicity and skin permeability. | The O/W micro emulsions containing a counter ion increased the skin permeability and lipophilicity of drug. | [ |
|
| |||
| Microsphere formulation | |||
| Benzoyl peroxide | To reduce skin irritation on topical treatment. | Cream containing microspheres of benzoyl peroxide offered favorable efficacy with a very low potential for irritation. | [ |
| Tretinoin | To reduce cutaneous irritation, including erythema, peeling, dryness, burning, and itching. | Microsphere formulation reduced local side effects and sustained release was achieved. | [ |
| All trans retinoic acid | To control the release of drug. | Controlled release of drug was produced by encapsulation of drug into the microsphere. | [ |
|
| |||
| Solid lipid nanoparticles formulation | |||
| Tretinoin | To evaluate the potential of a lipophilic drug with respect to primary skin irritation, in vitro occlusivity and skin permeation. | Lesser skin irritancy, greater skin tolerance, occlusivity, slow drug release, and increased permeability were observed with the developed tretinoin loaded SLN-based gels more than the commercial product. | [ |
| Isotretinoin | To evaluate skin penetration | SLN loaded with isotretinoin significantly increased the accumulative uptake of drug into the skin and enhanced the skin permeation. | [ |
| All trans retinoic acid | To produce comedolytic effect and reduce skin irritation. | SLN produced comedolytic effects and epidermal thickening with reduced skin irritation. | [ |
| Sphingosome | To increase skin permeation of drug. | Sphingosome SLN enhanced the permeation of the drug through the skin to acne lesion. | [ |
| Cyproterone acetate (CPA) | To reduce side effect and improve skin penetration and absorption. | CPA attached to SLN increased skin penetration at least four-fold over the uptake from cream and nanoemulsion. Incorporation of drug into the lipid matrix of NLC resulted in a 2 to 3 fold increase in CPA absorption. | [ |
| Triclosan | To increase stability, skin retention and permeability. | Triclosan nanoparticle increased the stability and showed higher retention and permeability than conventional cream formulation. | [ |
|
| |||
| Hydrogel formulation | |||
| Triclosan | To increase the permeability through skin. | Triclosan permeability was increased by using transcutol as a permeation enhancer. | [ |
| Tretinoin | To increase release permeation and reduce skin irritation of tretinoin. | The complexation of tretinoin with dimethyl- | [ |
|
| |||
| Aerosol foams formulation | |||
| Juniper oil | To reduce the volatility and maintain antibacterial activity. | Juniper oil solid lipid microparticles substantially maintain the oil loaded inside their lipidic structure, reducing its volatility and retaining its antibacterial activity. | [ |
(a) Systemic treatment
| Antibiotic | Name | Dose | Duration | Drawbacks |
|---|---|---|---|---|
| Oral antibiotics | ||||
| Tetracyclines | Tetracycline, Oxytetracycline | 250–500 mg twice daily | 4–6 months | Gastrointestinal upset, vaginal candidiasis, decreased compliance |
| Doxycycline | 50–100 mg twice daily | 4–6 months | Gastrointestinal upset, photosensitivity | |
| Minocycline | 50–100 mg twice daily | 4–6 months | Vertigo, hyperpigmentation of skin and oral mucosa, expensive | |
| Lymecycline | 150–300 mg daily | 4–6 months | ||
| Macrolides | Erythromycin | 500 mg twice daily | 4–6 months | Gastrointestinal upset, vaginal candidiasis, emergence of resistance of |
| Azithromycin | 250 mg three times a week | 4–6 months | Gastrointestinal upset |
(b) Hormonal treatment
| Name | Dose | Duration | Drawbacks |
|---|---|---|---|
| Spironolactone | 25–100 mg twice daily | 6 months | Menstrual irregularities, contraindicated in pregnancy |
| Prednisone | 2.5–5 mg daily | Indefinitely | Adrenal suppression |
| Dexamethasone | 0.125–0.5 mg daily | Indefinitely | Adrenal suppression |
| Cyproterone acetate/ethinyl estradiol (oral contraceptives) | 2 mg/35–50 | 6 months | Vascular thrombosis, melasma, weight gain |
| Levonorgestrel/ethinyl estradiol | 100 | 6 months | Vascular thrombosis, melasma, weight gain |